THE CHILDRENS HOSPITAL OF PHILADELP
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $133.8M
- Transactions
- 8,240
- Companies
- 40
- Average per transaction
- $16,234
Who reported the payments
| Pfizer | $22,514,894 |
| Spark Therapeutics, Inc. | $11,543,021 |
| Novartis | $10,131,107 |
| Vertex | $6,753,281 |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,443,902 |
| Gilead | $5,299,773 |
| E.r. Squibb & Sons, L.L.C. | $4,808,981 |
| Amgen | $4,338,813 |
| Jazz Pharmaceuticals Inc. | $3,413,610 |
| Biogen | $3,159,264 |
| Eli Lilly | $3,013,340 |
| Eisai Inc. | $2,664,914 |
| Travere Therapeutics, Inc. | $2,549,270 |
| Sanofi US Services Inc. | $2,200,170 |
| Sarepta Therapeutics, Inc. | $2,152,061 |
| Modernatx, Inc. | $2,138,514 |
| Ultragenyx Pharmaceutical Inc. | $2,114,555 |
| Regeneron | $2,067,752 |
| AbbVie | $1,926,293 |
| Genetix Biotherapeutics Inc | $1,855,251 |
| Bayer | $1,771,613 |
| AstraZeneca | $1,699,874 |
| Jubilant Draximage Inc. | $1,694,550 |
| PTC Therapeutics, Inc. | $1,661,893 |
| Seagen Inc. | $1,605,500 |
| Ionis Pharmaceuticals, Inc. | $1,478,378 |
| Merck | $1,197,941 |
| Zealand Pharma A/s | $1,147,486 |
| Rhythm Pharmaceuticals, Inc. | $948,660 |
| ZOLL Medical Corporation | $770,761 |
| F. Hoffmann-la Roche AG | $734,933 |
| Novartis Pharma AG | $731,651 |
| Sanofi | $676,704 |
| Alnylam Pharmaceuticals Inc. | $672,336 |
| Janssen Research & Development, LLC | $666,520 |
| Ipsen Bioscience Inc. | $655,216 |
| Foundation Medicine, Inc. | $622,500 |
| X4 Pharmaceuticals, Inc. | $601,309 |
| Genentech, Inc. | $492,650 |
| UCB SA | $459,541 |